AAIC 2025 Abstract·25 DecThe HOPE4MCI study: AGB101 treatment normalizes aberrant network activity and slows entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriersTrial in peopleInterventionsPaper